Abstract
Rationale
The goal of this paper is to briefly overview human studies that have examined pharmacological agents designed to enhance working memory function, with the idea of providing clues as to promising avenues to follow for the development of drugs likely to enhance working memory and other cognitive processes in individuals with schizophrenia.
Objectives
We reviewed the studies that have used pharmacological agents designed to target the dopamine system, the noradrenergic system, the acetycholine system, the serotonin system, and the glycine site on NMDA receptors.
Results
There are a large number of studies suggesting that dopamine agents can enhance working memory, though there remain conflicting issues regarding the role that baseline performance plays in modulating the influence of drug and the importance of different dopamine receptors. There is also consistent evidence that cholinesterase inhibitors can enhance working memory function, potentially through improved encoding of the information. There is less consistent evidence that noradrenergic alpha-2 agonists consistently improve working memory in humans, despite the large animal literature suggesting that these agents should have a beneficial effect on memory. As of yet, there is little evidence that agents targeting the glycine site of the NMDA receptor improve working memory, and data to suggest that enhancement of the serotonin system impairs working memory.
Conclusions
Compounds geared towards enhancing the dopamine system and the acetycholine system remain promising avenues for the development of pro-cognitive drugs, though further work is clearly needed on developing agents that may more selectively target specific receptors.
Similar content being viewed by others
References
Abi-Dargham A, Mawlawi O, Lombardo I, Gil R, Martinez D, Huang Y, Hwang DK, Keilp J, Kochan L, Van Heertum R, Gorman JM, Laruelle M (2002) Prefrontal dopamine D1 receptors and working memory in schizophrenia. J Neurosci 22:3708–3719
Arnsten AFT, Contant TA (1992) Alpha-2 adrenergic agonists decrease distractability in aged monkeys performing the delayed response task. Psychopharmacology 108:159–169
Arnsten AFT, Goldman-Rakic PS (1995) Alpha-2-adrenergic mechanisms in prefrontal cortex associated with cognitive decline in aged nonhuman primates. Science 230:1273–1276
Arnsten AF, Goldman-Rakic PS (1998) Noise stress impairs prefrontal cortical cognitive function in monkeys: evidence for a hyperdopaminergic mechanism. Arch Gen Psychiatry 55:362–368
Arnsten AF, Cai JX, Murphy BL, Goldman-Rakic PS (1994) Dopamine D1 receptor mechanisms in the cognitive performance of young adult and aged monkeys. Psychopharmacology 116:143–151
Arnsten AFT, Cai JX, Goldman-Rakic PS (1998) The alpha-2 adrenergic agonist guanfacine improves memory in aged monkeys without sedative or hypotensive side-effects. J Neurosci 8:4287–4298
Baddeley AD (1986) Working memory. Oxford University Press, Oxford University Press
Barch DM (2003) Cognition in schizophrenia: Is working memory working? Curr Direct Psychol Sci 12:146
Barch DM, Carter CS, Braver TS, McDonald A, Sabb FW, Noll DC, Cohen JD (2001) Selective deficits in prefrontal cortex regions in medication naive schizophrenia patients. Arch Gen Psychiatry 50:280–288
Barch DM, Csernansky J, Conturo T, Snyder AZ, Ollinger J (2002) Working and long-term memory deficits in schizophrenia. Is there a common underlying prefrontal mechanism? J Abnorm Psychol 111:478–494
Barch DM, Carter CS, MacDonald AW 3rd, Braver TS, Cohen JD (2003) Context processing deficit in schizophrenia: diagnostic specificity, 4-week course, and relationships to clinical symptoms. J Abnorm Psychol 112:132–143
Bartholomeusz CF, Box G, Van Rooy C, Nathan PJ (2003) The modulatory effects of dopamine D1 and D2 receptor function on object working memory in humans. J Psychopharmacol 17:9–15
Berman T, Douglas VI, Barr RG (1999) Effects of methylphenidate on complex cognitive processing in attention deficit hyperactivity disorder. J Abnorm Psychol 108:90–105
Bruder G, Kayser J, Tenke C, Rabinowicz E, Friedman M, Amador X, Sharif Z, Gorman J (1998) The time course of visuospatial processing deficits in schizophrenia: an event-related brain potential study. J Abnorm Psychol 107:399–411
Buchanan RW, Summerfelt A, Tek C, Gold JM (2003) An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia. Schizophr Res 59:29–33
Cai JX, Arnsten AFT (1997) Dose-dependent effects of the dopamine D1 receptor agonists A77636 or SKF81297 on spatial working memory in aged monkeys. J Pharmacol Exp Ther 283:183–189
Callicott JH, Bertolino A, Mattay VS, Langheim FJ, Duyn J, Coppola R, Goldberg TE, Weinberger DR (2000) Physiological dysfunction of the dorsolateral prefrontal cortex in schizophrenia revisited. Cereb Cortex 10:1078–1092
Callicott JH, Egan MF, Mattay VS, Bertolino A, Bone AD, Verchinski B, Weinberger DR (2003) Abnormal fMRI response of the dorsolateral prefrontal cortex in cognitive intact siblings of patients with schizophrenia. Am J Psychiatry 160:709–719
Castner SA, Williams GV, Goldman-Rakic PS (2000) Reversal of antiphychotic induced working memory deficits by short term dopamine D1 receptor stimulation. Science 287:2020–2022
Cohen JD, Servan-Schreiber D (1992) Context, cortex and dopamine: a connectionist approach to behavior and biology in schizophrenia. Psychol Rev 99:45–77
Coleman MJ, Cook S, Matthysse S, Barnard J, Lo Y, Levy DL, Rubin DB, Holzman PS (2002) Spatial and object working memory impairments in schizophrenia patients: A bayesian item-response theory analysis. J Abnorm Psychol 111:425–435
Costa A, Peppe A, Dell’Agnello G, Carlesimo GA, Murri L, Bonuccelli U, Caltagirone C (2003) Dopaminergic modulation of visual-spatial working memory in Parkinson’s disease. Dement Geriatr Cognit DIsord 15:55–66
Coull JT, Middleton HC, Robbins TW, Sahakian BJ (1995a) Clonidine and diazepam have differential effects on tests of attention and learning. Psychopharmacology 120:322–332
Coull JT, Middleton HC, Robbins TW, Sahakian BJ (1995b) Contrasting effects of clonidine and diazepam on tests of working memory and planning. Psychopharmacology 120:311–321
D’Esposito M, Aguirre GK, Zarahn E, Ballard D, Shin RK, Lease J (1998) Functional MRI studies of spatial and nonspatial working memory. Cognit Brain Res 7:1–13
Daniel DG, Berman KF, Weinberger DR (1989) The effect of apomorphine on regional cerebral blood flow in schizophrenia. J Neuropsychiatr 1:377–384
Daniel DG, Weinberger DR, Jones DW, R. ZJ, Coppola R, Handel S, Bigelow LB, Goldberg TE, Berman KF, Kleinman JE (1991) The effect of amphetamine on regional cerebral blood flow during cognitive activation in schizophrenia. J Neurosci 11:1907–1917
de Sonneville LM, Njiokiktjien C, Bos H (1994) Methylphenidate and information processing: part 1: differentiation between responders and nonresponders; part 2: efficacy in responders. J Clin Exp Neuropsychol 16:877–897
Durstewitz D, Kelc M, Gunturkun O (1999) A neurocomputational theory of the dopaminergic modulation of working memory functions. J Neurosci 19:2807–2822
Durstewitz D, Seamans JK, Sejnowski TJ (2000) Dopamine-mediated stabilization of delay-period activity in a network model of prefrontal cortex. J Neurophysiol 83:1733–1750
Egan MF, Goldberg TE, Kolachana BS, Callicott JH, Mazzanti CM, Straub RE, Goldman D, Weinberger DR (2001) Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci USA 98:6917–6922
Elliott R, Sahakian BJ, Matthews K, Bannerjea A, Rimmer J, Robbins TW (1997) Effects of methylphenidate on spatial working memory and planning in healthy young adults. Psychopharmacology 131:196–206
Evins AE, Amico E, Posever TA, Toker R, Goff DC (2002) d-Cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia. Schizophr Res 56:19–23
Farmer CM, O’Donnell BF, Niznikiewicz MA, Vaglmaier MM, McCarley RW, Shenton ME (2000) Visual perception and working memory in schizotypal personality disorder. Am J Psychiatry 157:781–786
Fields RB, Van Kammen DP, Peters JL, Rosen J, Van Kammen WB, Nugent A, Stipetic M, Linnoila M (1988) Clonidine improves memory function in schizophrenia independently from change in psychosis. Schizophr Res 1:417–423
Fournet N, Roulin LJ, Moreadu O, Naegele B, Pellat J (2000) Working memory function in medicated Parkinson’s disease and the effect of withdrawal of dopaminergic medication. Neuropsychology 14:247–253
Friedman JI, Adler DN, Temporini HD, Kemether E, Harvey PD, White L, Parrella M, Davis KL (2001) Guanfacine treatment of cognitive impairment in schizophrenia. Neuropsychopharmacology 25:402–409
Friedman JI, Adler D, Howanitz E, Harvey PD, Brenner G, Temporini HD, White L, Parrella M, Davis KL (2002) A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizohprenia. Biol Psychiatry 51:349–357
Furey ML, Pietrini P, Haxby JV, Alexander GE, Lee HC, vanMeter J, Grady CL, Shetty U, Rapoport SI, Schapiro MB, Freo U (1997) Cholinergic stimulation alters performance and task-specific regional cerebral blood flow during working memory. Proc Natl Acad Sci 94:6512–6516
Furey ML, Pietrini P, Alexander GE, Schapiro MB, Horwitz B (2000a) Cholinergic enhancement improves performance on working memory by modulating the functional activity in distinct brain regions: a positron emission tomography regional cerebral blood flow study in healthy humans. Brain Res Bull 51:213–218
Furey ML, Pietrini P, Haxby JV (2000b) Cholinergic enhancement and increased selectivity of perceptual processing during working memory. Science 290:2315–2319
Goff DC, Tsai G, Levitt JJ, Amico E, Manoach D, Schoenfeld DA, Hayden DL, McCarley RW, Coyle JT (1999) A placebo-controlled trial of d-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry 56:21–27
Gold JM, Carpenter C, Randolph C, Goldberg TE, Weinberger DR (1997) Auditory working memory and Wisconsin Card Sorting Test performance in schizophrenia. Arch Gen Psychiatry 54:159–165
Goldberg TE, Bigelow LB, Weinberger DR, Daniel DG, Kleinman JE (1991) Cognitive and behavioral effects of the coadministration of dextroamphetamine and haloperidol in schizophrenia. Am J Psychiatry 148:78–84
Goldberg TE, Egan MF, Gscheidle T, Coppola R, Weickert T, Kolachana BS, Goldman D, Weinberger DR (2003) Executive subprocesses in working memory: relationship to catechol-O-methyltransferase Val158Met genotype and schizophrenia. Arch Gen Psychiatry 60:889–896
Goldman-Rakic PS (1991) Prefrontal cortical dysfunction in schizophrenia: the relevance of working memory. In: Carroll BJ, Barrett JE (eds) Psychopathology and the Brain. Raven, New York, pp 1–23
Goldman-Rakic PS (1995) Cellular basis of working memory. Neuron 14:477–485
Goldman-Rakic PS (1996) The prefrontal landscape: Implications of functional architecture for understanding human mentation and the central executive. In: Roberts AC, Robbins TW, Weiskrantz L (eds) The prefrontal cortex: executive and cognitive functions. Oxford University Press, Oxford, pp 87–103
Goldman-Rakic PS, Muly EC, Williams GV (2000) D1 receptors in prefrontal cells and circuits. Brain Res Rev 31:295–301
Jakala P, Riekkinen M, Sirvio J, Koivisto E, Kejonen K, Vanhanen M, Riekkinen M (1999a) Guanfacine, but not clonidine, improves planning and working memory. Neuropsychopharmacology 20:460–470
Jakala P, Sirvio J, Riekkinen M, Koivisto E, Kejonen K, Vanhanen M, Riekkinen P (1999b) Guanfacine and clonidine, alpha-2 agonists, improved paired associated learning, but not delayed matching to sample, in humans. Neuropsychopharmacology 20:119–130
Kimberg DY, D’Esposito M (2003) Cognitive effects of the dopamine receptor agonist pergolide. Neuropsychologica 41:1020–1027
Kimberg DY, D’Esposito M, Farah MJ (1997) Effects of bromocriptine on human subjects depend on working memory capacity. Neuroreport 8:381–385
Kimberg DY, Aguirre GK, Lease J, D’Esposito M (2001) Cortical effects of bromocriptine, a D-2 dopamine receptor agonist, in human subjects, revealed by fMRI. Hum Brain Map 12:246–257
Kirrane RM, Mitropoulou V, Nunn M, New AS, Harvey PD, Schopick F, Silverman JM, Siever LJ (2000) Effects of amphetamine on visuospatial working memory performance in schizophrenia spectrum personality disorder. Neuropsychopharmacology 22:14–18
Kirrane RM, Mitropoulou V, Nunn M, Silverman JM, Siever LJ (2001) Physostigmine and cognition in schizotypal personality disorder. Schizophr Res 48:1–5
Lange KW, Robbins TW, Marsden CD, Owen AM, Paul GM (1992) l-Dopa withdrawal in Parkinson’s disease selectively impairs cognitive performance in tests sensitive to frontal lobe dysfunction. Psychopharmacology 107:394–404
Lencz T, Bilder RM, Turkel E, Goldman RS, Robinson D, Kane JM, Lieverman JA (2003) Impairments in perceptual competency and maintenance on a visual delayed match-to-sample test in first-episode schizophrenia. Arch Gen Psychiatry 60:238–243
Lenzenweger MF, Gold JM (2000) Auditory working memory and verbal recall memory in schizotypy. Schizophr Res 42:101–110
Levy DL, Smith M, Robinson D, Jody D, Lerner G, Alvir J, Geisler SH, Szymanski SR, Gonzalez A, Mayerhoff DI, Lieberman JA, Mendell NR (1993) Methylphenidate increases thought disorder in recent onset schizophrenics, but not in normal controls. Biol Psychiatry 34:507–514
Luciana M, Collins PF (1997) Dopamine modulates working memory for spatial but not object cues in normal humans. J Cognit Neurosci 4:58–68
Luciana M, Depue RA, Arbisi P, Leon A (1992) Facilitation of working memory in humans by a D2 dopamine receptor agonist. J Cognit Neurosci 4:58–68
Luciana M, Collins PF, Depue RA (1995) DA and 5-HT influences on spatial working memory functions of prefrontal cortex. Cognitive Neuroscience Society Second Annual Meeting, San Francisco, Calif., p 43
Luciana M, Collins PF, Depue RA (1998) Opposing roles for dopamine and serotonin in the modulation of human spatial working memory functions. Cereb Cortex 8:218–226
Luciana M, Burgund ED, Berman M, Hanson KL (2001) Effects of tryptophan loading on verbal, spatial, and affective working memory functions in healthy adults. J Psychopharmacol 15:219–230
Magill RA, Water WF, Bray GA, Volaufova J, Smith SR, Lieberman HR, McNevin N, Ryan DH (2003) Effects of tyrosine, phentermine, caffeine, d-amphetamine and placebo on cognitive and motor performance deficits during sleep deprivation. Nutr Neurosci 6:237–246
Malhotra AK, Kestler LJ, Mazzanti CM, Bates JA, Goldberg TE, Goldman D (2002) A functional polymorphism in the COMT gene and performance on a test of prefrontal cognition. Am J Psychiatry 159:652–654
Malpalani C, Pillon B, Dubois B, Agid Y (1994) Impaired simultaneous cognitive task performance in Parkinson’s disease: a dopamine-related dysfunction. Neurology 44:319–326
Mattay VS, Berman KF, Ostrem JL, Esposito G, Van Horn JD, Bigelow LB, Weinberger DR (1996) Dextroamphetamine enhances “neural network-specific” physiological signals: a positron-emission tomography rCBF study. J Neurosci 15:4816–4822
Mattay VS, Callicott JH, Bertolino A, Heaton I, J. FA, Coppola R, Berman KF, Goldberg TE, Weinberger DR (2000) Effects of dextroamphetamine on cognitive performance and cortical activation. Neuroimage 12:268–275
Mattay VS, Tessitore A, Callicott JH, Bertolino A, Goldberg TE, Chase TN, Hyde TM, Weinberger DR (2002) Dopaminergic modulation of cortical function in patients with Parkinson’s disease. Ann Neurol 51:156–164
Mattay VS, Goldberg TE, Fera F, Hariri AR, Tessitore A, Egan MF, Kolachana BS, Callicott JH, Weinberger DR (2003) Catechol O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine. Proc Natl Acad Sci 100:6186–6191
Mehta MA, Owen AM, Sahakian BJ, Mavaddat N, Pickard JD, Robbins TW (2000) Methylphenidate enhances working memory by modulating discrete frontal and parietal lobe regions in the human brain. J Neurosci 20:1–6
Mehta MA, Swainson R, Gogilvie AD, Sahakian BJ, Robbins TW (2001) Improved short-term spatial memory but impaired reversal learning following the dopamine D2 agonist bromocriptime in human volunteers. Psychopharmacology 159:10–20
Mintzer M, Griffiths RR (2003) Triazolam-amphetamine interaction: dissociation of effects of memory versus arousal. J Pharmacol 17:17–29
Mitropoulou V, Harvey PD, Maldari LA, Moriarty PJ, New AS, Silverman JM, Siever LJ (2002) Neuropsychological performance in schizotypal personality disorder: evidence regarding diagnostic specificity. Biol Psychiatry 52:1175–1182
Muller U, von Cramon Y, Pollmann S (1998) D1- versus D2-receptor modulation of visuospatial working memory in humans. J Neurosci 18:2720–2728
Newcomer JW, Farber NB, Selke G, Melson AK, Jevtovic-Todorovic V, Olney JW (1998) Guanabenz effects on NMDA antagonist-induced mental symptoms in humans. Soc Neurosci Abstr, pp 525
Owen AM, Iddon JL, Hodges JR, Summers BA, Robbins TW (1997) Spatial and non-spatial working memory at different stages of Parkinson’s disease. Neuropsycholgia 35:519–532
Park S, Holzman PS (1992) Schizophrenics show spatial working memory deficits. Arch Gen Psychiatry 49:975–982
Park S, McTigue K (1997) Working memory and the syndromes of schizotypal personality. Schizophr Res 26:213–220
Park S, Holzman PS, Goldman-Rakic PS (1995a) Spatial working memory deficits in the relatives of schizophrenic patients. Arch Gen Psychiatry 52:821–828
Park S, Holzman PS, Lenzenweger MF (1995b) Individual differences in spatial working memory in relation to schizotypy. J Abnorm Psychol 104:355–363
Pigeau R, Naitoh P, Buguet A, McCann C, Baranski J, Talor M, Thompson M, Mack I (1995) Modafinil, d-amphetamine and placebo during 64 hours of sustained mental work: I. Effects on mood, fatigue, cognitive performance and body temperature. J Sleep Res 4:212–228
Rabinowicz EF, Silipo G, Goldman RS, Javitt DC (2000) Auditory sensory dysfunction in schizophrenia: imprecision or distractibility. Arch Gen Psychiatry 57:1131–1137
Roitman SE, Mitropoulou V, Keefe RS, Silverman JM, Serby M, Harvey PD, Reynolds DA, Mohs RC, Siever LJ (2000) Visuospatial working memory in schizotypal personality disorder patients. Schizophr Res 41:447–455
Sawaguchi T, Goldman-Rakic PS (1994) The role of D1-dopamine receptor in working memory: local injections of dopamine antagonists into the prefrontal cortex of rhesus monkeys performing an oculomotor delayed-response task. J Neurophysiol 71:515–528
Seeman P, Madras BK (1998) Anti-hyperactivity medication: methylphenidate and amphetamine. Mol Psychiatr 3:386–396
Siegel BV, Trestman RL, O’Faithbheartaigh S, Mitropoulou V, Amin F, Kirrane RM, Silverman JM, Schmeidler J, Keefe RS, Siever LJ (1996) d-Amphetamine challenge effects on Wisconsin card sort test performance in schizotypal personality disorder. Schizophr Res 20:29–32
Taylor FB, Russo J (2001) Comparing guanfacine and dextroamphetamine for the treatment of adults attention-deficit/hyperactivity disorder. J Clin Pharmacol 21:223–228
Tek C, Gold JM, Blaxton T, Wilk C, McMahon RP, Buchanan RW (2002) Visual perceptual and working memory impairments in schizophrenia. Arch Gen Psychiatry
Turner D, Robbins TW, Clark L, Aron AR, Dowson J, Sahakian BJ (2003) Relative lack of cognitive effects of methylphenidate in elderly male volunteers. Psychopharmacology 168:455–464
Umbricht D, Schmid L, Koller R, Vollenweider FX, Hell D, Javitt DC (2000) Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia. Arch Gen Psychiatry 57:1139–47
Van Kammen DP, Bunney WE, Docherty JP, Marder SR, Ebert MH, Rosenblatt JE, Rayner JN (1982) d-Amphetamine-induced heterogeneous changes in psychotic behavior in schizophrenia. Am J Psychiatry 139:991–997
Williams GV, Goldman-Rakic PS (1995) Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. Nature 376:572–575
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Barch, D.M. Pharmacological manipulation of human working memory. Psychopharmacology 174, 126–135 (2004). https://doi.org/10.1007/s00213-003-1732-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00213-003-1732-3